TechCrunch
SEPTEMBER 9, 2021
Neuroglee Therapeutics , a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston. Neuroglee gets $2.3
TechCrunch
DECEMBER 3, 2020
Alzheimer’s is the leading cause of dementia and caregivers are often overwhelmed, without enough support. Neuroglee , a Singapore-based health tech startup, wants to help with a digital therapeutic platform created to treat patients in the early stages of the disease. million in pre-seed funding. The round was led by Eisai Co.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
HPA
MARCH 15, 2022
We’re excited to share that metaMe Health , a prescription digital therapeutics (PDT) company, today announced raising $2.2M metaMe Health is the developer of Regulora®, the first FDA-authorized PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults. in funding.
HPA
MARCH 15, 2022
We’re excited to share that metaMe Health , a prescription digital therapeutics (PDT) company, today announced raising $2.2M metaMe Health is the developer of Regulora®, the first FDA-authorized PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults. in funding.
American Entrepreneurship
JANUARY 18, 2024
in income replacement grants and mentorship to first-time entrepreneurs, creating 10 new businesses and helping fuel innovation in strategic sectors The New Jersey Economic Development Authority (NJEDA) today announced the inaugural cohort of the New Jersey Innovation Fellows (NJIF) program. First-in-nation program will provide $3.6M
TechCrunch
NOVEMBER 3, 2021
BrainCheck , a Houston- and Austin-based company developing cognitive healthcare software to aid physicians in detecting and managing this type of care, raised $10 million in Series B funding to expand its R&D and go-to-market capabilities as it works on new digital therapeutics for Alzheimer’s and related dementias.
TechCrunch
MAY 12, 2023
Amongst these questions are actual costs of therapies, reimbursement coverage, the commercialisation strategy for psychedelic drug development companies, resource bottlenecks with the therapists’ supply and infrastructure, etc,” they told TechCrunch+. Drug development is very costly, and start-ups are having a harder time raising cash.
Expert insights. Personalized for you.
93 
Let's personalize your content